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response to IA treatments. Other factors including joint loading, activity
level, and inﬂammation may also inﬂuence SF lubricant composition
over time. As such, the present study suggests that boundary lubricant
composition of SF in OA joints can change over time with repeated IA
treatment, and that this response to IA CST or HA treatment appears to
vary between individuals. IA PRG4 has been shown to stimulate
endogenous production of PRG4 in preclinical models, and PRG4 can
affect boundary lubricating and rheological properties of HAþPRG4
solutions and SF in vitro. Furthermore, PRG4 concentrations appear to
be decreased in some chronic OA patients, suggesting that future study
of IA PRG4HA is warranted and could provide further insight into the
mechanism of action of IA HA(PRG4) biotherapeutic treatments. The
outcome of such future analysis of SF lubricant composition, boundary
lubricating function, and pain relief provided by IA PRG4HA might
ultimately be beneﬁcial for chronic, symptomatic OA patients with
compromised SF boundary lubricant composition.
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FULL-THICKNESS CARTILAGE DEFECTS REPAIR WITH
MICROFRACTURE TECHNIQUE AND INTRA-ARTICULAR INJECTION
OF A SMALL MOLECULE COMPOUND KARTOGENIN
X. Xu, Y. Shen, D. Shi, Q. Jiang. Sports Med. and Adult Reconstruction,
Nanjing, China
Purpose: To evaluate the outcome of . Methods: Full-thickness cartilage
defects were created in patellar groove of both femurs in 24 female New
Zealand White rabbits. The defects were then performed microfracture
surgery. The animals were divided into two groups according to post-
operative treatment. 12 rabbits were treated with intra-articular
injection of kartogenin (KGN) for once a week (Group A); the other 12
rabbits were treated with intra-articular injection of DMSO for once a
week (Group B). Animals were scariﬁced at 1 and 3months after
injection. 6 rabbits from each group at every time interval were killed
and the knees were harvested. The defects repair was assessed byMacroscopic, hematoxylin and eosin staining, toluidine blue staining,
and immunohistochemical stain for collagen type II. Differences
between groups at each time point were analyzed.
Results: 1month after treatment, no signiﬁcant differencewas detected
between Group A and Group B. After 3 months’ weekly injection, Group
A showed signiﬁcantly better macroscopic view, quality of repair tissue
and lateral integration than Group B.
Conclusions: 3 months’ intra-articular injection of KGN after
microfracture signiﬁcantly improve the effectiveness of treatment
full-thickness cartilage defects in comparition with isolated micro-
fractures.
Therapy: Biological
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THE S100A9 INHIBITOR PAQUINIMOD (ABR-215757) REDUCES
SYNOVIAL ACTIVATION, OSTEOPHYTE FORMATION AND CARTILAGE
DAMAGE IN EXPERIMENTAL OSTEOARTHRITIS
R.F. Schelbergen y, A.B. Blom y, T. Leanderson z, H. Eriksson x,
W.B. van den Berg y, P.M. van der Kraan y, P.L. van Lent y. yRadboud Univ.
Med. center, Nijmegen, Netherlands; z Lund Univ., Lund, Sweden; xActive
Biotech AB, Lund, Sweden
Purpose: Synovial activation is present in a large subset of osteo-
arthritis (OA) patients and it is thought to play an important role in the
development of OA pathology. Previously, we found that activated
macrophage products S100A8 and S100A9 are involved in cartilage
degradation and synovial activation during experimental OA. Paquini-
mod is a quinoline-3-carboxamide compound with immunomodula-
tory properties that is currently in clinical development for treatment of
systemic sclerosis. It targets the S100A9 protein and blocks the binding
of S100A9 to RAGE and TLR-4.In the current study we investigated the
effect of the S100A9-blocking compound paquinimod on experimental
osteoarthritis with different degrees of synovial activation.
Methods: Collagenase induced OA (CIOA) was induced by two times
intra-articular injection of 1U collagenase and DMM was induced by
transsection of the medial anterior meniscotibial ligament leading to
destabilization of the medial meniscus (DMM), both in C57Bl6 mice.
Paquinimod (3,75 mg/kg) was administered in the drinking water 4
days before induction of OA in both CIOA and DMM and refreshed
twice a week. Whole knee joints were isolated and embedded in
parafﬁn for histological sectioning. Synovial thickening and cellu-
larity was measured using an arbitrary score from 0-3. OA-like car-
tilage pathology was scored using a modiﬁed Pritzker OARSI score.
Osteophyte size was measured by a blinded observer using image
analysis software.
Results: First, we assessed the effect of paquinimod on DMM devel-
opment on day 56. Synovial activation in this surgical model is low, as
are S100A8/A9 levels in the synovium. No differences were observed on
osteophyte size between paquinimod-treated and non-treated animals
at both medial tibia and medial femur. Furthermore, OA-like cartilage
pathology was only signiﬁcantly reduced by paquinimod-treatment at
Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489 S483the medial femur (-64%), not at other surfaces and not in the total joint
score (-16%).
Then, we treated collagenase-induced OA (CIOA) with paquinimod and
evaluated the effects on day 42. In CIOA, synovial activation is high and
S100A8/A9 levels in the synovium are signiﬁcantly higher than those in
DMM. Synovial activation was signiﬁcantly reduced by paquinimod-
treatment at the medial side of the patella-femur region (-57%).
Osteophyte size was signiﬁcantly reduced at the medial femur (-66%)
and cruciate ligaments (-67%). Finally, OA-like cartilage pathology in
CIOA was signiﬁcantly reduced after paquinimod treatment on the
medial side of both tibia and femur (-47% and -75% respectively) as well
as in the total joint score (-46%) (Figure 1).
Conclusions: Paquinimod administered in the drinking water reduces
synovial activation, osteophyte formation and OA-like cartilage path-
ology in CIOA. In contrast, in an experimental OA model where synovial
activation is nearly absent (DMM), the effect of paquinimod is marginal.
Paquinimod could prove a very promising treatment for osteoarthritis
patients with high synovial activation by blocking S100A9.
882
A FUSION PROTEIN OF IL4 AND IL10 (IL4-10 SYNERKINE), IS VERY
EFFECTIVE IN PROTECTING CARTILAGE FROM BLOOD-INDUCED
DAMAGE
L.F. van Vulpen, M.E. van Meegeren, C. Steen-Louws, C.E. Hack,
S.C. Mastbergen, F.P. Lafeber. UMC Utrecht, Utrecht, Netherlands
Purpose: Interleukin 4 (IL4), IL10 or the combination of both protects
cartilage from blood-induced damage in vitro. Because IL4 and IL10 use
different signaling pathways they are able to exert different, but also
potentially additive effects. It has been postulated that they can act in
synergy enhancing their beneﬁcial effects and controlling their indi-
vidual adverse effects. Therefore a combination of IL4 and IL10 might be
the best option to administer in vivo.
To overcome the low bioavailability of IL4 and IL10 in vivo, a fusion
protein has been developed: IL4-10 synerkine. It has been demon-
strated that this novel drug inhibits numerous pro-inﬂammatory
cytokines secreted by monocytes and T-cells. This study investigates
whether this IL4-10 synerkine protects against blood-induced cartilage
damage similarly as the combination of the individual components.
Methods: Human cartilage explants were exposed to 50% v/v whole
blood for 4 days and simultaneously to a broad concentration range (0-
100 ng/mL) of the IL4-10 synerkine. Effects of 10 ng/mL IL4-10 syn-
erkine were compared to the same concentrations of the individual
cytokines and the combination. Cartilage matrix proteoglycan turnover
was assessed after a recovery period of 12 days. Moreover, the inﬂuence
of IL4-10 synerkine (10 ng/mL) and its individual components on levels
of IL1b and IL6 were investigated in a 4 days 50% v/v whole blood
culture.
Results: Exposure to 50% v/v whole blood resulted in a clear statistical
signiﬁcant decrease of proteoglycan (PG) synthesis rate (-74%; p ¼
0.012) and an increase of PG release (þ92%, p ¼ 0.017) compared toFigure – Effect of the IL4-10 synerkine compared to 1L4. IL10 and the
combination of both cytokines (all 10ng/mL) on cartilage proteoglycan
synthesis rate (A) and release (B) (n¼8 individual donors). Median values
 interquartile range are depicted. Hash tags indicate a statistically sig-
niﬁcant difference compared to 50% v/v blood (p<0.05). asterisks indicate
a statistically signiﬁcant difference compared to control cartilage
(p<0.05).control. Adding of IL4-10 synerkine, resulted in a clear dose-response
curve, leading to full normalisation of PG synthesis rate and -release at
higher concentrations (>10 ng/mL). These results were similar to the
effect of the two individual cytokines combined (see ﬁgure). The indi-
vidual cytokines had amore distinct proﬁle where IL4 was superior over
IL10 (see ﬁgure). Moreover, addition of IL4-10 synerkine reduced IL1b
and IL6 production in whole blood cultures to control levels (both p <
0.05), similar to the combination of IL4 plus IL10 (p ¼ 0.180 and p ¼
0.173, respectively).
Conclusions: IL4-10 synerkine strongly protects against blood-induced
cartilage damage in vitro, presumably at least in part by reduction of
pro-inﬂammatory cytokines including IL1b and IL6. Considering better
bioavailability and more easy application of this synerkine compared to
the individual cytokines, testing the IL4-10 synerkine in an in vivo
model of blood-induced cartilage damage is warranted.
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THE HIGHS AND LOWS OF TRANSLATIONAL DRUG
DEVELOPMENT: ANTIBODY-MEDIATED INHIBITION OF ADAMTS-5
FOR OSTEOARTHRITIS DISEASE MODIFICATION
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F. Liu y, E.I. Rossman y, J. Renninger y, X. Wu y, L. Abberley y, R.E. Miller z,
S. Foulcer x, K.W. Chaudhary y, C. Genell y, D. Murphy y, P.B. Tran z,
S. Apte x, A-M. Malfait z, C.C. Maier y, C.J. Matheny y. yGlaxoSmithKline,
King of Prussia, PA, USA; zRush Univ., Chicago, IL, USA; xCleveland Clinic
Lerner Res. Inst., Cleveland, OH, USA
Purpose: Aggrecanase activity, most notably ADAMTS-5, has been
widely implicated as a pathogenic factor in cartilage degradation.
Therefore, highly selective and potent monoclonal antibodies (mAbs) to
both ADAMTS-5 and ADAMTS-4 were developed and experimental
systems were utilized to assess target engagement and modulation of
disease-related and safety endpoints with the intent of selecting a
candidate and supporting clinical development in osteoarthritis (OA).
Methods/Results: In a surgical mouse model of OA, both ADAMTS-5
and ADAMTS-4-speciﬁc mAbs bound within cartilage following sys-
temic administration, demonstrating access to the anticipated site of
action, whereas structural disease modiﬁcation and associated allevia-
tion of pain-related behavior were only observed with ADAMTS-5 mAb
treatment. Likewise, ex vivo treatment of human OA cartilage demon-
strated a preferential role for ADAMTS-5 inhibition over ADAMTS-4, as
measured by aggrecan-derived 374ARGS neoepitope release in explant
cultures and was most evident in a distinct subset of patients where
elevated 374ARGS neoepitope levels were present in explants prior to
treatment. Notably, suppression of 374ARGS neoepitope release was
sustained for weeks after a single treatment of human cartilage explants
and in cynomolgus monkeys, consistent with a high afﬁnity antibody/
antigen interaction and slowADAMTS-5 turnover that could translate to
less frequent clinical dosing. As a result an ADAMTS-5 selective mon-
oclonal antibody (GSK2394002) was progressed for preclinical devel-
opment as a potential OA disease modifying therapeutic.
While desired pharmacology was observed in explant cartilage and
disease models, ADAMTS-5 is also expressed in cardiovascular (CV)
tissue. Recently it was reported that knockout mice show devel-
opmental heart valve defects and altered vascular and ﬁbroblast pro-
teoglycan processing. Along with these observations, an initial
histologic cardiac signal in cynomolgus monkeys (subendocardial
hemorrhage) prompted a careful assessment of CV function in a set of
dedicated safety pharmacology studies. In these studies, increased
mean arterial pressure (MAP) was observed within days after>3 mg/kg
dosing and ST segment elevation was noted on 24 hour continuous ECG
monitoring>30mg/kg. Surprisingly, these effects were sustained for up
to 8 months following a single dose and MAP was increased upon
repeated low dose administration suggesting the effects are cumulative
and, unlike the systemic pharmacodynamic marker signal, once
induced they may not be readily reversible. Although a potential
mechanistic link between ADAMTS-5 activity and versican processing is
demonstrated, the cause of these cardiovascular observations is cur-
rently unknown. In a parallel general toxicology study, there were no
histologic or biochemical correlates to the CV ﬁndings and no evidence
of off-target mechanisms could be identiﬁed using in vitro tests
examining cardiac conductance, ion channels, or binding selectivity in
protein arrays.
Conclusions: The ﬁndings support a hypothesis set forth from knockout
mouse studies that ADAMTS-5 is the major aggrecanase involved in
